DEA Issues First Schedule III Medical Cannabis Registrations, But Compliance Questions Remain

Cannabis Law Blog
Nov 19, 2026

Medical marijuana operators saw significant developments on the federal level recently: (1) issuances of the first federal registrations under the new Schedule III framework, and (2) a Drug Enforcement Administration (DEA) informational publication on what actions “Timely Applicants” (defined below) can and cannot do while registrations are pending.

On October 30, 2026, the U.S. Department of Justice announced that the DEA had begun issuing the first federal registrations to qualified state-licensed medical marijuana dispensaries. More than 900 dispensaries across seven states received registrations in this first wave, marking the first and most significant federal integration of state medical cannabis programs in U.S. history. Approvals were issued to dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia, which all currently permit only medical marijuana.

For cannabis operators, the DEA issued an informational publication related to the entities with whom Schedule III medical marijuana registrants can transact, how supply chains should be structured, and what happens in dual-use states like Ohio, where medical and adult-use markets operate side by side. Businesses may soon face difficult decisions regarding inventory sourcing, trading partners, and operational segregation.

A Brief Refresher

As previously discussed by Frantz Ward’s Cannabis Law and Policy group, the Department of Justice’s April 2026 action placed FDA-approved marijuana products and marijuana products regulated under qualifying state medical marijuana licenses into Schedule III while broader federal rescheduling proceedings continue separately. Importantly, this action did not legalize recreational cannabis and did not remove federal regulation. Instead, it created a new federal regulatory pathway for qualifying medical marijuana activities.

The October 30 announcement represents the first significant implementation milestone of that framework. DEA confirmed that more than 900 dispensaries have now received federal registrations after satisfying federal eligibility requirements, including successful completion of DEA pre-registration investigations. Notably, state licensure alone does not qualify an operator for federal registration.

Manufacturers and distributors remain under DEA review and face additional federal requirements, including inspections, production controls, and quota determinations.

The Most Consequential Development: A Closed Supply Chain

While registrations are being issued, DEA’s informational publication addressed “Timely Applicants”: entities that applied for registration during the initial application window of April 28, 2026, to June 26, 2026. Nearly 7,000 medical cannabis businesses applied for registration during this window, including 4,197 dispensaries, 2,086 manufacturers, and 710 distributors. Those applicants may continue conducting medical marijuana activities while their applications remain pending, but, according to the DEA, beginning November 29, 2026, timely applicants and operators who already have been issued their federal registrations generally may conduct Schedule III medical marijuana activities only with:

  • Other federally registered Schedule III medical marijuana entities; or
  • Other “Timely Applicants” whose applications remain pending.

Conversely, DEA states that registrants and timely applicants may not lawfully engage in Schedule III medical marijuana transactions with entities that failed to apply during the designated application period or otherwise lack DEA registration status. DEA further warns that such transactions could become grounds for denial of an application or revocation of an existing registration.

The practical effect is the creation of a federally recognized “closed-loop” distribution system for Schedule III medical marijuana registrants. The strictest interpretation of this letter is that timely applicants whose suppliers and business partners did not timely apply may have to stop engaging in Schedule III medical marijuana sales with operators that are neither “Timely Applicants” nor registered with the DEA by November 29, 2026, or risk denial of a pending application or revocation of a registration already issued.

If DEA maintains its current interpretation, federally registered medical cannabis businesses may need to carefully evaluate whether their suppliers, manufacturers, processors, distributors, and testing partners qualify as DEA registrants or protected timely applicants. Transactions involving non-registered market participants could raise federal compliance concerns even if those transactions are permissible under state law.

Potential Challenges

That said, state-licensed businesses that missed the initial 60-day complete-application window and timely applicants facing proposed denial may have fact-specific grounds to challenge the DEA approach. For instance, 21 C.F.R. § 1301.13(k)(7) states that a timely applicant “may engage in the manufacture, distribution, and/or dispensing of marijuana or products containing marijuana for medical purposes in conformity with a state-issued license during the pendency of the application” without saying anything related to a closed-loop system that excludes other state license holders to whom an applicant can buy or sell medical marijuana “in conformity with a state-issued license[.]”

Other provisions expressly place registered manufacturers, distributors, and dispensers generally within a federally registered chain. One potential argument concerns notice: the interim provision did not expressly prohibit timely applicants from buying from or selling to state licensees lacking timely-applicant or registrant status. October’s publication expressly announces that restriction and warns of possible denial or revocation. Affected businesses may question whether they had adequate notice that missing the window would also exclude them from transactions with timely applicants and registrants after November 29.

Potential claims include APA notice-and-comment objections to a binding, materially consequential restriction not clearly contained in the interim provision; arbitrary-and-capricious objections based on tension with state-system reliance, least-disruption goals, and broad interim authority; and fair-notice/due-process objections.

An Order to Show Cause only proposes denial of an applicant’s registration, and presumably many recipients of the Order to Show Cause will pursue their arguments as part of the administrative hearing process, challenging the statutory, evidentiary, and procedural bases relied upon by the DEA. Other license holders may file challenges in court raising similar arguments in advance of the November 29 deadline.

Operators considering a challenge should also evaluate whether to submit an application. A denial ordinarily creates a final agency decision that may be appealed. If DEA issues an Order to Show Cause, the applicant generally has 30 days to request a hearing. Missing that deadline may waive both the hearing and the ability to preserve issues for judicial review.

Why This Matters in Ohio

Ohio presents one of the more challenging compliance environments because it operates a dual-use program where operators conduct both medical and adult-use cannabis activities.

Historically, many Ohio operators have managed integrated operations serving both patients and adult-use consumers within the state’s broader regulated cannabis market. Federal Schedule III registration complicates that model, creating a potentially significant divergence between state compliance and federal compliance.

This scrutiny of dual-use systems is especially critical in light of an October 27, 2026, Order to Show Cause whereby the DEA proposes to deny a Minnesota dispensary’s application in part because Minnesota permits a single licensee to serve both medical patients and adult-use customers. DEA concluded the state’s framework fails to provide “robust protections” against diversion and falls outside DEA’s definition of a “state medical marijuana license.” DEA characterizes dispensing for recreational use as “per se diversion” under the Controlled Substances Act and states that it “cannot permit any applicant operating under” Minnesota’s regime to access the federal closed system.

DEA also faulted Minnesota for allowing veterans to qualify for medical cannabis without a physician’s written certification. Adult-use programs do not require physician certification at all. That reasoning suggests that even broader federal rescheduling may not resolve the registration problem for operators participating in adult-use markets.

For Ohio operators, key questions include:

  • Whether medical and adult-use inventory streams must be more clearly segregated;
  • Whether operators serving both markets can maintain federal registration eligibility until the broader rescheduling effort is completed;
  • How vertically integrated operators will document compliant sourcing;
  • Whether medical products can continue moving through supply chains that also serve adult-use markets; and
  • How future state licensing or ownership changes could affect federal registration status.

While DEA has not yet published detailed answers to these questions, the agency’s emphasis on a closed distribution system suggests operators should begin assessing supply-chain relationships now rather than waiting for formal enforcement activity.

Colorado Faces Similar Questions

Colorado presents a different but equally complex challenge. Because Colorado’s adult-use market is substantially larger than its medical market, many businesses operate primarily in the recreational sector, having allowed their medical licenses to lapse or maintaining such licenses to engage in a substantially smaller volume of medical marijuana transactions. DEA’s position that federally registered medical marijuana entities may engage in Schedule III medical marijuana transactions only with registered or timely-applicant counterparts could require significant restructuring for portions of the Colorado industry.

Operators will need to assess whether existing business relationships satisfy federal requirements and whether their supply chain is distinctly “medical-only” in order to preserve Schedule III protections.

For large multi-state operators with assets in both Ohio and Colorado, developing consistent compliance frameworks across jurisdictions may become a significant operational priority.

Due Diligence Is Becoming a Federal Requirement

Another notable aspect of DEA’s publication is its emphasis on due diligence. DEA specifically recommends that businesses verify the status of trading partners by:

  • Obtaining application confirmations from timely applicants;
  • Verifying document control numbers through DEA systems;
  • Obtaining copies of DEA registrations where applicable;
  • Confirming active state licensure; and
  • Maintaining records documenting those verification efforts.

These are not merely best practices. DEA expressly warns that transactions with unauthorized entities could affect registration status. As a result, compliance teams should expect heightened scrutiny of vendor qualification procedures and supply-chain documentation.

Testing Laboratories Remain a Potential Bottleneck

DEA also acknowledged a practical problem affecting many state markets: the limited availability of DEA-registered cannabis testing laboratories.

Recognizing that some states require testing before products can be sold, DEA announced that it does not currently intend to penalize registrants or timely applicants that send de minimis quantities of Schedule III medical marijuana to certain non-DEA-registered laboratories under limited circumstances. The exception is narrow and primarily applies when no DEA-registered laboratory is reasonably available and state law limits interstate testing options. Nevertheless, this letter highlights another area where federal and state regulatory systems have not yet fully aligned.

What Cannabis Businesses Should Be Doing Now

For operators in Ohio, Colorado, and other medical cannabis states, the immediate focus should be on compliance. Businesses should consider:

  1. Mapping all current supply-chain relationships.
  2. Identifying which counterparties have obtained DEA registrations or timely-applicant status.
  3. Evaluating whether medical and adult-use operations require greater operational/legal separation.
  4. Updating vendor onboarding and due diligence procedures.
  5. Reviewing inventory controls, recordkeeping systems, and transaction documentation.
  6. Monitoring further DEA information regarding manufacturers, processors, distributors, and laboratories.

Looking Ahead

The first wave of federal registrations confirms that the Schedule III medical cannabis framework is no longer theoretical. The federal government has begun integrating state-regulated medical marijuana businesses into a controlled-substance regulatory system that includes federal registration, recordkeeping, security, and supply-chain requirements.

Yet many of the most important questions remain unanswered, especially for dual-use states where medical and adult-use markets are deeply interconnected. As DEA continues reviewing applications from manufacturers and distributors and develops additional guidance, operators should expect increased attention to supply-chain integrity, trading partner verification, and operational segregation.

Federal rescheduling has also been silent on existing state-based geographic limitations, neither expressly authorizing nor prohibiting interstate transactions. The DEA letter limits activities based on the federal status of the business partner, not by geography. A timely applicant’s authorization to conduct business is “pursuant to its state medical marijuana license,” which presumably prohibits interstate commerce.

For years, state-legal cannabis companies have only needed to focus on state regulatory requirements. But with rescheduling comes an added layer of, at times, incongruent federal regulatory requirements. Cannabis companies can no longer ignore federal regulations and must evaluate their business practices and supply chain in light of DEA’s oversight – at least until things change again.

If you have questions about how rescheduling and other policy changes at the federal level affect your state-licensed cannabis business, please do not hesitate to reach out to a member of the Frantz Ward Cannabis Law and Policy group.

This post is for general information and does not constitute legal or tax advice.